Final Follow-Up Data Support Boston Scientific’s Watchman Stroke-Prevention Device
The final follow-up data from the CAP and CAP2 registries support left-atrial appendage closure with Watchman as an alternative to long-term anticoagulation in patients with nonvalvular atrial fibrillation.
You may also be interested in...
The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.
Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020
Boston Scientific said in an earnings call it expects the coronavirus outbreak may lead to a $10m to $40m loss in first-quarter sales as a result of lower procedures volumes and disrupted supply chains in China. For the fourth quarter, Boston Scientific reported $2.9bn in sales.
An analysis of pooled five-year data from the PROTECT AF and PREVAIL trials, show left-atrial appendage closure to prevent stroke in patients with atrial fibrillation is not only cost‐effective compared to treatment with warfarin and other anticoagulant drugs, but saves money over time.